DLL3 and small cell lung carcinoma: Based on this knowledge, modulation of the Notch pathway enables potential therapeutic strategies—for example, in the treatment of small-cell lung cancer (SCLC), where the broadly expressed DLL3 ligand in SCLC cells is targeted using antibodies and specific inhibitors (Zhang et al., 2023).